Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease

December 2024 in “ Pharmaceutics ”

Mingqin Shi, Xinyao Li, Liwei Xing, Zhenmin Li, Shaobing Zhou, Zihui Wang, Xiang Zou, Yuqing She, Rong Zhao, Dongdong Qin

Polycystic Ovary Syndrome PCOS hyperandrogenism insulin resistance inflammation nanomaterial-based drug delivery liposomes chitosan nanoparticles metal nanoparticles selenium nanoparticles silver nanoparticles

Studysummary This review discusses the potential of using nanomaterial-based drug delivery systems to improve the treatment of polycystic ovary syndrome but reports no new clinical results, highlighting future research directions. Our plain-language summary of this paper — not a Tressless recommendation.

The document explores the potential of nanomaterial-based drug delivery systems for treating Polycystic Ovary Syndrome (PCOS), a complex disorder involving hyperandrogenism, insulin resistance, and inflammation. Current treatments have side effects, but nanomaterials like liposomes, chitosan nanoparticles, and metal nanoparticles (e.g., selenium and silver) offer targeted delivery, enhanced bioavailability, and reduced toxicity. These systems can improve drug stability and efficacy, reduce inflammation, and address metabolic and ovarian dysfunctions. Despite promising advancements, further research is needed to assess nanoparticle toxicity and transition these technologies from lab to clinical use.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

8 / 8 results

research Exploring the Antioxidative Effects of Ginger and Cinnamon: A Comprehensive Review of Evidence and Molecular Mechanisms Involved in Polycystic Ovary Syndrome and Other Oxidative Stress-Related Disorders

24 citations , March 2024 in “Antioxidants”

In this review, researchers reported that cinnamon and ginger supplementation may benefit PCOS patients by improving hormonal status, lipid profiles, obesity, and insulin resistance through oxidative stress and inflammation reduction.

Recommendations From The 2023 International Evidence-Based Guideline For The Assessment And Management Of Polycystic Ovary Syndrome

research Recommendations From The 2023 International Evidence-Based Guideline For The Assessment And Management Of Polycystic Ovary Syndrome

2 citations , August 2023 in “Human Reproduction”

This update of the 2023 International Guideline for PCOS offers refined diagnostic criteria and management recommendations, emphasizing evidence-based care, but notes that research quality remains low to moderate.

research Weekly Treatment with SAMiRNA Targeting the Androgen Receptor Ameliorates Androgenetic Alopecia

3 citations , January 2022 in “Scientific Reports”

This study found that SAMiRNA-AR68, a nanomedicine targeting androgen receptor mRNA, increased hair counts in androgenetic alopecia patients with no observed side effects.

research Effectiveness of Low-Dose Ethinylestradiol/Cyproterone Acetate and Ethinylestradiol/Desogestrel with and without Metformin on Hirsutism in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Triple-Dummy Study

5 citations , July 2020 in “PubMed”

This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.

research Polycystic Ovary Syndrome: Comprehensive Overview

257 citations , July 2018 in “Obstetrics & Gynecology”

This review discusses the various phenotypes and diagnostic challenges of polycystic ovary syndrome, highlighting its complex pathophysiology and associated health risks, and reports no new clinical results.

research Secondary Amenorrhea: Causes, Diagnosis, and Treatment

4 citations , August 2017 in “The Nurse Practitioner”

This article discusses the systematic diagnostic evaluation of secondary amenorrhea and provides guidance for referral considerations; it reports no new research findings.

research Current Aspects of Polycystic Ovary Syndrome: A Literature Review

15 citations , December 2016 in “Revista Da Associacao Medica Brasileira”

This review examines the literature on polycystic ovary syndrome, focusing on its pathogenesis, diagnosis, and links to cardiovascular and hypertensive disorders, but presents no new clinical findings.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (PCOS)

4025 citations , December 2003 in “Human Reproduction”

This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.